SR3 Stock Overview
Designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
STAAR Surgical Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.55 |
| 52 Week High | US$47.99 |
| 52 Week Low | US$24.62 |
| Beta | 0.62 |
| 11 Month Change | -7.19% |
| 3 Month Change | -12.11% |
| 1 Year Change | -16.91% |
| 33 Year Change | -70.72% |
| 5 Year Change | -23.50% |
| Change since IPO | 604.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| SR3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.1% | 2.4% | 0.8% |
| 1Y | -16.9% | -5.0% | 9.1% |
Return vs Industry: SR3 underperformed the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: SR3 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| SR3 volatility | |
|---|---|
| SR3 Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SR3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SR3's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 1,057 | Tom Frinzi | www.staar.com |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
STAAR Surgical Company Fundamentals Summary
| SR3 fundamental statistics | |
|---|---|
| Market cap | €1.25b |
| Earnings (TTM) | €20.75m |
| Revenue (TTM) | €325.12m |
64.6x
P/E Ratio4.1x
P/S RatioIs SR3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SR3 income statement (TTM) | |
|---|---|
| Revenue | US$341.22m |
| Cost of Revenue | US$72.57m |
| Gross Profit | US$268.66m |
| Other Expenses | US$246.88m |
| Earnings | US$21.78m |
Last Reported Earnings
Sep 27, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 78.73% |
| Net Profit Margin | 6.38% |
| Debt/Equity Ratio | 0% |
How did SR3 perform over the long term?
See historical performance and comparison